Results 71 to 80 of about 4,105,314 (99)

Bidirectional Neoadjuvant Chemotherapy for Patients with Gastric Cancer and Synchronous Peritoneal Metastases (GCPMs): Results of a Western Phase II Study. [PDF]

J Clin Med
Biacchi D, Angrisani M, Picone V, Scuto D, Gallotti MG, Accarpio F, Iafrate F, Masci G, Iannone I, Spagnoli A, Sammartino P.   +10 more
europepmc   +1 more source

Gastrointestinal CancerEmerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review. [PDF]

Oncologist
Tops-Welten MW, Galanos LJK, Creemers GJ, Luyer MDP, De Hingh IHJT, van Hellemond IEG.   +5 more
europepmc   +1 more source

Modified scoring system for the quantitative assessment of histological regression in peritoneal carcinomatosis after pressurized intraperitoneal aerosol chemotherapy: A pilot study. [PDF]

Oncol Lett
Abbas M, Ramspott JP, Chourio Barboza DE, Pascher A, Wardelmann E, Sporn JC.   +5 more
europepmc   +1 more source

Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial. [PDF]

Front Oncol
Nakamura B, Senguttuvan R, Ruel NH, Frankel PH, Yost SE, Cole S, Chang S, Jung A, Eng M, Tinsley R, Stewart D, Wang E, Cohen J, Villella J, Whelan RL, Merchea A, DePeralta DK, Cristea M, Wakabayashi MT, Raoof M, Dellinger TH.   +20 more
europepmc   +1 more source

Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies. [PDF]

Cancers (Basel)
Pietrasik Z, Kapała M, Pietrasik J, Stefaniak M, Szubert S, Książek K, Mikuła-Pietrasik J.   +6 more
europepmc   +1 more source

Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapy. [PDF]

NPJ Precis Oncol
Bishara I, Cosgrove PA, Majumdar S, Egelston CA, Flores OC, Nakamura B, Ruel N, Frankel PH, Yost SE, Chang S, Jung A, Cristea M, Raoof M, Bild AH, Nath A, Dellinger TH.   +15 more
europepmc   +1 more source

The Role of Inflammatory Biomarkers in PIPAC: Predicting Survival and Treatment Completion in Patients with Peritoneal Metastasis. [PDF]

J Cancer
Roensholdt S, Graversen M, Detlefsen S, Fristrup C, Pfeiffer P, Mortensen MB.   +5 more
europepmc   +1 more source

Oligometastatic pancreatic cancer: current state of management and emerging therapies. [PDF]

Oncologist
Khomiak A, Balmaceda NB, Ghaffar SA, Lieu CH, Del Chiaro M, Messersmith WA, Lentz RW.   +6 more
europepmc   +1 more source

Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes. [PDF]

ESMO Open
Sundar R, Chia DKA, Zhao JJ, Lee ARYB, Kim G, Tan HL, Pang A, Shabbir A, Willaert W, Ma H, Huang KK, Hagihara T, Tan ALK, Ong CJ, Wong JSM, Seo CJ, Walsh R, Chan G, Cheo SW, Soh CCC, Callebout E, Geboes K, Ng MCH, Lum JHY, Leow WQ, Selvarajan S, Hoorens A, Ang WH, Pang H, Tan P, Yong WP, Chia CSL, Ceelen W, So JBY.   +33 more
europepmc   +1 more source

Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed therapy of patients with malignant pleural effusion and pleural metastasis. [PDF]

Pleura Peritoneum
Hansen PS, Graversen M, Detlefsen S, Ainsworth AP, Mortensen MB.   +4 more
europepmc   +1 more source